pharma · Lymphoma · Primary immune thrombocytopenia (ITP)
Hutchison Medi Pharma
Hutchmed Europe B.V.
Hutchmed Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Lymphoma, Primary immune thrombocytopenia (ITP). NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0
Shanghai, CN HQ
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Shanghai, CN
- Employees
- 6
- Programs
- 4
- Drugs
- 6
- Patents
- 0
2022-523-GLOB1
Phase 1 · other · Primary immune thrombocytopenia (ITP)
2022-523-GLOB1 for Primary immune thrombocytopenia (ITP) is a Phase 1 program (other) at Hutchmed Europe B.V. with 1 ClinicalTrials.gov record(s).
Internal code 2022-523-GLOB1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hutchmed Europe B.V.
- Phase
- Phase 1
- Modality
- other
- Indication
- Primary immune thrombocytopenia (ITP)
- Status
- active
- Trials
- 1